IMVT peer analysis
Immunovant (IMVT) against its competitors: price, today's move, 1-year return and market value side by side.
IMVT and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACRS Aclaris Therapeutics | $3.78 | -4.79% | 51.81% | $615.29M |
| ANAB AnaptysBio | $47.02 | -2.61% | 28.93% | $1.44B |
| ANNX Annexon | $3.93 | -2.96% | 34.13% | – |
| CABA Cabaletta Bio | $1.51 | -4.73% | -38.87% | $256.01M |
| CGEM Cullinan Therapeutics | $14.93 | -0.70% | 97.42% | – |
| IMUX Immunic | $7.51 | -3.66% | -4.23% | $102.47M |
| QTTB Q32 Bio | $8.91 | 0.45% | 222.83% | – |
| TGTX TG Therapeutics | $59.97 | -1.99% | 76.26% | $9.36B |
| TRAX First Tracks Biotherapeutics | $44.98 | -0.22% | – | – |
| ZBIO Zenas BioPharma | $27.67 | -2.54% | -7.40% | – |
| IMVT Immunovant | $28.45 | -2.47% | 14.63% | $6.03B |
- IMVT's peers: ACRS (Aclaris Therapeutics), ANAB (AnaptysBio), ANNX (Annexon), CABA (Cabaletta Bio), CGEM (Cullinan Therapeutics), IMUX (Immunic), QTTB (Q32 Bio), TGTX (TG Therapeutics).
Updated 2026-11-02 23:11 UTC